290 related articles for article (PubMed ID: 37096862)
1. Recent developments for new investigational JAK inhibitors in psoriatic arthritis.
Caso F; Costa L; Triggianese P; Maione F; Bertolini N; Vastarella M; Chimenti MS; Tasso M
Expert Opin Investig Drugs; 2023 May; 32(5):361-371. PubMed ID: 37096862
[TBL] [Abstract][Full Text] [Related]
2. JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: a critical review of clinical trials.
Keeling S; Maksymowych WP
Expert Rev Clin Immunol; 2021 Jul; 17(7):701-715. PubMed ID: 33944642
[TBL] [Abstract][Full Text] [Related]
3. A novel treatment for psoriatic arthritis: Janus kinase inhibitors.
Chen M; Dai SM
Chin Med J (Engl); 2020 Apr; 133(8):959-967. PubMed ID: 32209886
[TBL] [Abstract][Full Text] [Related]
4. Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors.
Chimalakonda A; Burke J; Cheng L; Catlett I; Tagen M; Zhao Q; Patel A; Shen J; Girgis IG; Banerjee S; Throup J
Dermatol Ther (Heidelb); 2021 Oct; 11(5):1763-1776. PubMed ID: 34471993
[TBL] [Abstract][Full Text] [Related]
5. Relative efficacy and safety of Janus kinase inhibitors for the treatment of active psoriatic arthritis: a network meta-analysis.
Lee YH; Song GG
Z Rheumatol; 2023 Jun; 82(5):408-416. PubMed ID: 34716775
[TBL] [Abstract][Full Text] [Related]
6. Tofacitinib for the treatment of psoriasis and psoriatic arthritis.
Berekmeri A; Mahmood F; Wittmann M; Helliwell P
Expert Rev Clin Immunol; 2018 Sep; 14(9):719-730. PubMed ID: 30118353
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of Janus kinase inhibitors in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis.
Yang F; Lu C; Wang Y; Liu H; Leng X; Zeng X
Clin Rheumatol; 2023 Jun; 42(6):1593-1605. PubMed ID: 36763226
[TBL] [Abstract][Full Text] [Related]
8. JAK Inhibitors in Psoriatic Disease.
Megna M; Potestio L; Ruggiero A; Cacciapuoti S; Maione F; Tasso M; Caso F; Costa L
Clin Cosmet Investig Dermatol; 2023; 16():3129-3145. PubMed ID: 37927384
[TBL] [Abstract][Full Text] [Related]
9. English version of Japanese guidance for the use of oral Janus kinase inhibitors (JAK1 and TYK2 inhibitors) in the treatments of psoriasis.
Saeki H; Mabuchi T; Asahina A; Abe M; Igarashi A; Imafuku S; Okubo Y; Komine M; Takahashi K; Torii H; Morita A; Yotsuyanagi H; Watanabe A; Ohtsuki M;
J Dermatol; 2023 May; 50(5):e138-e150. PubMed ID: 37132187
[TBL] [Abstract][Full Text] [Related]
10. Targeted synthetic pharmacotherapy for psoriatic arthritis: state of the art.
Caso F; Navarini L; Ruscitti P; Chimenti MS; Girolimetto N; Del Puente A; Giacomelli R; Scarpa R; Costa L
Expert Opin Pharmacother; 2020 May; 21(7):785-796. PubMed ID: 32057269
[TBL] [Abstract][Full Text] [Related]
11. State of the art: approved and emerging JAK inhibitors for rheumatoid arthritis.
El Jammal T; Sève P; Gerfaud-Valentin M; Jamilloux Y
Expert Opin Pharmacother; 2021 Feb; 22(2):205-218. PubMed ID: 32967471
[TBL] [Abstract][Full Text] [Related]
12. Management of Axial Spondyloarthritis - Insights into Upadacitinib.
Braun J; Kiltz U; Baraliakos X
Drug Des Devel Ther; 2022; 16():3609-3620. PubMed ID: 36268520
[TBL] [Abstract][Full Text] [Related]
13. The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis.
Veale DJ; McGonagle D; McInnes IB; Krueger JG; Ritchlin CT; Elewaut D; Kanik KS; Hendrikx T; Berstein G; Hodge J; Telliez JB
Rheumatology (Oxford); 2019 Feb; 58(2):197-205. PubMed ID: 29618084
[TBL] [Abstract][Full Text] [Related]
14. Novel treatments with small molecules in psoriatic arthritis.
Hansen RB; Kavanaugh A
Curr Rheumatol Rep; 2014; 16(9):443. PubMed ID: 25027606
[TBL] [Abstract][Full Text] [Related]
15. Upadacitinib for the treatment of adult patients with active psoriatic arthritis.
Marchesoni A; Citriniti G; Girolimetto N; Possemato N; Salvarani C
Expert Rev Clin Immunol; 2024 May; 20(5):423-434. PubMed ID: 38155531
[TBL] [Abstract][Full Text] [Related]
16. Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 Pathway.
Loo WJ; Turchin I; Prajapati VH; Gooderham MJ; Grewal P; Hong CH; Sauder M; Vender RB; Maari C; Papp KA
J Cutan Med Surg; 2023; 27(1_suppl):3S-24S. PubMed ID: 36519621
[TBL] [Abstract][Full Text] [Related]
17. Evaluating upadacitinib for the treatment of psoriatic arthritis.
Akpabio A; Adebajo A
Expert Opin Pharmacother; 2022 Feb; 23(2):169-173. PubMed ID: 35014922
[TBL] [Abstract][Full Text] [Related]
18. Janus Kinase Inhibitors: Safety in Patients With Psoriatic Arthritis.
Nash P
J Rheumatol; 2022 Jun; 49(6 Suppl 1):44-47. PubMed ID: 35293326
[TBL] [Abstract][Full Text] [Related]
19. Performance of Janus kinase inhibitors in psoriatic arthritis with axial involvement in indirect comparison with ankylosing spondylitis: a retrospective analysis from pooled data.
Wang L; Ping X; Chen W; Xing W
Clin Rheumatol; 2021 May; 40(5):1725-1737. PubMed ID: 33067773
[TBL] [Abstract][Full Text] [Related]
20. Are Janus kinase inhibitors safe and effective in treating the key clinical domains of psoriatic arthritis? A systematic review and meta-analysis.
Harkins P; Burke E; Swales C; Silman A; Conway R
Int J Rheum Dis; 2023 Jan; 26(1):31-42. PubMed ID: 36184741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
